Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market capitaliz
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to
The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.
Major indices continue to climb Despite ongoing concerns over sticky inflation, high interest rates and geopolitical tensions. Many shares defy the traditional “sell in May and go away” adage.
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
If you are looking for dividend stocks to buy, you're at the right place; research shows that companies regularly raising payouts, known as “dividend growers,” boast compound annual returns of abo
Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' coval
Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc
Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insu
If you think you've missed the rally in high-flying growth stocks, think again. Even though the market is close to all-time highs, many well-known growth stocks still have plenty of room to run.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE